166 related articles for article (PubMed ID: 30293699)
1. Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors.
Carrozza F; Santoni M; Piva F; Cheng L; Lopez-Beltran A; Scarpelli M; Montironi R; Battelli N; Tamberi S
Crit Rev Oncol Hematol; 2018 Nov; 131():1-6. PubMed ID: 30293699
[TBL] [Abstract][Full Text] [Related]
2. An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
[TBL] [Abstract][Full Text] [Related]
3. Telomerase-Targeted Cancer Immunotherapy.
Mizukoshi E; Kaneko S
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013796
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
5. Uses of telomerase peptides in anti-tumor immune therapy.
Li H; Katik I; Liu JP
Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
[TBL] [Abstract][Full Text] [Related]
6. Telomeres and telomerase in T cells of tumor immunity.
Qian Y; Yang L; Cao S
Cell Immunol; 2014; 289(1-2):63-9. PubMed ID: 24727158
[TBL] [Abstract][Full Text] [Related]
7. Telomerase in cancer immunotherapy.
Liu JP; Chen W; Schwarer AP; Li H
Biochim Biophys Acta; 2010 Jan; 1805(1):35-42. PubMed ID: 19751801
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
9. Novel anticancer therapeutics targeting telomerase.
Ruden M; Puri N
Cancer Treat Rev; 2013 Aug; 39(5):444-56. PubMed ID: 22841437
[TBL] [Abstract][Full Text] [Related]
10. Antisense human telomerase reverse transcriptase could partially reverse malignant phenotypes of gastric carcinoma cell line in vitro.
Yang SM; Fang DC; Yang JL; Chen L; Luo YH; Liang GP
Eur J Cancer Prev; 2008 Jun; 17(3):209-17. PubMed ID: 18414191
[TBL] [Abstract][Full Text] [Related]
11. Telomerase based anticancer immunotherapy and vaccines approaches.
Kailashiya C; Sharma HB; Kailashiya J
Vaccine; 2017 Oct; 35(43):5768-5775. PubMed ID: 28893481
[TBL] [Abstract][Full Text] [Related]
12. Telomerase-based immunotherapy of cancer.
Carpenter EL; Vonderheide RH
Expert Opin Biol Ther; 2006 Oct; 6(10):1031-9. PubMed ID: 16989585
[TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity.
Natarajan S; Chen Z; Wancewicz EV; Monia BP; Corey DR
Oligonucleotides; 2004; 14(4):263-73. PubMed ID: 15665594
[TBL] [Abstract][Full Text] [Related]
14. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical localization of hTERT protein in human tissues.
Yan P; Benhattar J; Seelentag W; Stehle JC; Bosman FT
Histochem Cell Biol; 2004 May; 121(5):391-7. PubMed ID: 15138842
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.
Fan Y; Liu Z; Fang X; Ge Z; Ge N; Jia Y; Sun P; Lou F; Björkholm M; Gruber A; Ekman P; Xu D
Clin Cancer Res; 2005 Jun; 11(12):4331-7. PubMed ID: 15958614
[TBL] [Abstract][Full Text] [Related]
17. Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells.
Napier CE; Veas LA; Kan CY; Taylor LM; Yuan J; Wen VW; James A; O'Brien TA; Lock RB; MacKenzie KL
Biochim Biophys Acta; 2010 Oct; 1803(10):1142-53. PubMed ID: 20619302
[TBL] [Abstract][Full Text] [Related]
18. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
Pang JX
Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy advances in uro-genital malignancies.
Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells.
Mu X; Sang Y; Fang C; Shao B; Yang L; Yao K; Zhao X; Gou J; Wei Y; Yi T; Wu Y; Zhao X
Int J Oncol; 2015 Nov; 47(5):1901-11. PubMed ID: 26398907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
